BioWorld

March 16, 2005

Avastin's Survival Data In NSCLC Sends Genentech Soaring, Again

Genentech Inc.'s stock climbed 25 percent in late-day trading Monday after news that a Phase III trial of Avastin met its primary endpoint of survival in non-small-cell lung cancer patients. (BioWorld Today) Read More

ViaCell Gets Patent, Signs Deal With Genzyme; Stock Moves Up

In Very Early Going, Killing Cancer Cells Indiscriminately

CVBT Completes IPO, Gets $17M For Vascular Product

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 20, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 20, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...